Literature DB >> 33428039

Utility of Endoscopy in Hospitalized Patients with Gastrointestinal Hemorrhage and Pulmonary Hypertension.

Amandeep Singh1, Mohamed Tausif Siddiqui2, Wael Al-Yaman2, Rajat Garg3, Sanguk Jang2, Prabhleen Chahal2, John Vargo2.   

Abstract

BACKGROUND: Gastrointestinal hemorrhage (GIH) has been reported as one of the most common GI complications in patients with pulmonary hypertension (PH). There is paucity of data on the national burden of GIH in patients with PH. We aimed to assess the prevalence, trends and outcomes of endoscopic interventions in patients with PH who were admitted with GIH.
METHOD: We queried National Inpatient Sample (NIS) database from 2005 to 2014 and identified the patients hospitalized with primary or secondary discharge diagnosis of PH (ICD 9 CM Code: 416.0, 416.8, and 416.9). Using Clinical Classification Software Coding system (153) patients with concurrent diagnosis of GIH were then identified. We studied the prevalence and trends of GIH in PH, factors associated with GIH, use of endoscopy, factors associated with utilization of endoscopic interventions, endoscopy outcomes including mortality, and overall healthcare burden.
RESULTS: Out of 7,586,973 PH hospitalizations 3.2% (N = 246,358) had concurrent GIH, with a rising prevalence of GIH in PH patients during the last decade. Clinical predictors for GIH in PH included older age, congestive heart failure, anticoagulation therapy and concurrent alcohol abuse. Mean length of stay (LOS) in PH patients hospitalized with GIH was significantly higher than without GIH (8.6 vs. 6.4 days, p < 0.01) along with a significant increase in hospitalization cost ($20,189 vs. $14,807, p < 0.01). Similarly, odds of in-hospital mortality increase by ~ 1.5 times in PH patients with GIH than those without it (adjusted odds ratio [aOR: 1.45, 95%CI: 1.43-1.47]). Endoscopic interventions were performed in 48.6% of patients with PH and GIH during their hospitalization. Older patients were more likely to undergo endoscopy, as well as the patients who received blood transfusion, and those with hypovolemic shock. Patients with acute respiratory failure and acute renal failure were less likely to get endoscopy. Mean LOS in patients undergoing endoscopic intervention was significantly higher than those who did not receive any intervention (8.7 vs. 8.4 days, p < 0.01), without a substantial increase in hospitalization cost ($20,344 vs. $20,041, p < 0.01). Also, there was a significant decrease in in-hospital mortality in patients undergoing endoscopic interventions.
CONCLUSION: Concurrent GIH in patients with PH increases length of stay; healthcare costs and increases in-hospital mortality. Use of endoscopic interventions in these patients is associated with reduced length of stay, in-hospital mortality without significantly increasing the overall health care burden and should be considered in hospitalized patients with PH who are admitted with GIH. Future studies comparing GIH patients with and without PH should be done to assess if PH is a risk factor for worse outcomes. CLINICAL TRIAL REGISTRATION NUMBER: No IRB required due to use of national de-identified data.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Endoscopy; Gastrointestinal hemorrhage; Pulmonary hypertension

Mesh:

Year:  2021        PMID: 33428039      PMCID: PMC9206875          DOI: 10.1007/s10620-020-06803-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  20 in total

1.  Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

Authors:  David B Badesch; Steven H Abman; Gerald Simonneau; Lewis J Rubin; Vallerie V McLaughlin
Journal:  Chest       Date:  2007-06       Impact factor: 9.410

Review 2.  Bleeding events in pulmonary arterial hypertension.

Authors:  C F Opitz; W Kirch; E A Mueller; D Pittrow
Journal:  Eur J Clin Invest       Date:  2009-06       Impact factor: 4.686

3.  Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.

Authors:  Neena S Abraham; Peter A Noseworthy; Xiaoxi Yao; Lindsey R Sangaralingham; Nilay D Shah
Journal:  Gastroenterology       Date:  2016-12-30       Impact factor: 22.682

Review 4.  Upper gastrointestinal bleeding risk scores: Who, when and why?

Authors:  Sara Monteiro; Tiago Cúrdia Gonçalves; Joana Magalhães; José Cotter
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

5.  Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension.

Authors:  Ivo R Henkens; Thomas Hazenoot; Anco Boonstra; Menno V Huisman; Anton Vonk-Noordegraaf
Journal:  Eur Respir J       Date:  2012-08-30       Impact factor: 16.671

6.  The in-hospital mortality rate for upper GI hemorrhage has decreased over 2 decades in the United States: a nationwide analysis.

Authors:  Marwan S Abougergi; Anne C Travis; John R Saltzman
Journal:  Gastrointest Endosc       Date:  2014-12-05       Impact factor: 9.427

7.  Disparities in the prevalence of comorbidities among US adults by state Medicaid expansion status.

Authors:  Tomi Akinyemiju; Megha Jha; Justin Xavier Moore; Maria Pisu
Journal:  Prev Med       Date:  2016-04-16       Impact factor: 4.018

Review 8.  Changing epidemiology and etiology of upper and lower gastrointestinal bleeding.

Authors:  Kathryn Oakland
Journal:  Best Pract Res Clin Gastroenterol       Date:  2019-04-17       Impact factor: 3.043

9.  Impact of Comorbidities Among Medicaid Enrollees With Chronic Obstructive Pulmonary Disease, United States, 2009.

Authors:  Gloria Westney; Marilyn G Foreman; Junjun Xu; Marshaleen Henriques King; Eric Flenaugh; George Rust
Journal:  Prev Chronic Dis       Date:  2017-04-13       Impact factor: 2.830

10.  Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers.

Authors:  Tamara Roldan; Juan J Rios; Elena Villamañan; Aaron B Waxman
Journal:  Pulm Circ       Date:  2017-07-14       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.